Associations - EGFR exon 19 deletion

EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval Thorac Cancer - 6 days (New C3) afatinib Sensitive : A1 Thorac Cancer - 6d	afatinib Sensitive: A1 - Approval Thorac Cancer - 6 days afatinib Sensitive : A1 Thorac Cancer - 6 days - (New C3)
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	erlotinib Sensitive: A1 - Approval Thorac Cancer - 6 days (New C3) erlotinib Sensitive : A1 Thorac Cancer - 6d	erlotinib Sensitive: A1 - Approval Thorac Cancer - 6 days erlotinib Sensitive : A1 Thorac Cancer - 6 days - (New C3)
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	AZD3759 Sensitive: C3 – Early Trials EClinicalMedicine - 1 week (New C3) AZD3759 Sensitive : C3 EClinicalMedicine - 1wk	AZD3759 Sensitive: C3 – Early Trials EClinicalMedicine - 1 week AZD3759 Sensitive : C3 EClinicalMedicine - 1 week - (New C3)
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	amivantamab-vmjw + lazertinib Sensitive: B - Late Trials Nat Med - 2 weeks (New C3) amivantamab-vmjw + lazertinib Sensitive : B Nat Med - 2wk	amivantamab-vmjw + lazertinib Sensitive: B - Late Trials Nat Med - 2 weeks amivantamab-vmjw + lazertinib Sensitive : B Nat Med - 2 weeks - (New C3)
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	lazertinib Sensitive: B - Late Trials J Thorac Oncol - 2 weeks (New B) lazertinib Sensitive : B J Thorac Oncol - 2wk	lazertinib Sensitive: B - Late Trials J Thorac Oncol - 2 weeks lazertinib Sensitive : B J Thorac Oncol - 2 weeks - (New B)
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	U3-1402 Sensitive: C2 – Inclusion Criteria J Clin Oncol - 2 weeks (New C3) U3-1402 Sensitive : C2 J Clin Oncol - 2wk	U3-1402 Sensitive: C2 – Inclusion Criteria J Clin Oncol - 2 weeks U3-1402 Sensitive : C2 J Clin Oncol - 2 weeks - (New C3)
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	amivantamab-vmjw Sensitive: B - Late Trials J&J Press Release - 3 weeks (New B) amivantamab-vmjw Sensitive : B J&J Press Release - 3wk	amivantamab-vmjw Sensitive: B - Late Trials J&J Press Release - 3 weeks amivantamab-vmjw Sensitive : B J&J Press Release - 3 weeks - (New B)
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	dacomitinib Sensitive: A1 - Approval dacomitinib Sensitive : A1	dacomitinib Sensitive: A1 - Approval dacomitinib Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	erlotinib + ramucirumab Sensitive: A1 - Approval erlotinib + ramucirumab Sensitive : A1	erlotinib + ramucirumab Sensitive: A1 - Approval erlotinib + ramucirumab Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	bevacizumab + erlotinib Sensitive: A2 - Guideline bevacizumab + erlotinib Sensitive : A2	bevacizumab + erlotinib Sensitive: A2 - Guideline bevacizumab + erlotinib Sensitive : A2
EGFR exon 19 deletion	Lung Non-Squamous Non-Small Cell Cancer	EGFR exon 19 deletion	Lung Non-Squamous Non-Small Cell Cancer	osimertinib Sensitive: A2 - Guideline osimertinib Sensitive : A2	osimertinib Sensitive: A2 - Guideline osimertinib Sensitive : A2
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR inhibitor Sensitive: B - Late Trials EGFR inhibitor Sensitive : B	EGFR inhibitor Sensitive: B - Late Trials EGFR inhibitor Sensitive : B
EGFR exon 19 deletion	Lung Adenocarcinoma	EGFR exon 19 deletion	Lung Adenocarcinoma	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	icotinib Sensitive: B - Late Trials icotinib Sensitive : B	icotinib Sensitive: B - Late Trials icotinib Sensitive : B
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	gefitinib + rivoceranib Sensitive: B - Late Trials gefitinib + rivoceranib Sensitive : B	gefitinib + rivoceranib Sensitive: B - Late Trials gefitinib + rivoceranib Sensitive : B
EGFR exon 19 deletion	Lung Non-Squamous Non-Small Cell Cancer	EGFR exon 19 deletion	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: B - Late Trials bevacizumab + atezolizumab Sensitive : B	bevacizumab + atezolizumab Sensitive: B - Late Trials bevacizumab + atezolizumab Sensitive : B
EGFR exon 19 deletion	Lung Adenocarcinoma	EGFR exon 19 deletion	Lung Adenocarcinoma	afatinib Sensitive: B - Late Trials afatinib Sensitive : B	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	gefitinib + ramucirumab Sensitive: B - Late Trials gefitinib + ramucirumab Sensitive : B	gefitinib + ramucirumab Sensitive: B - Late Trials gefitinib + ramucirumab Sensitive : B
EGFR exon 19 deletion	Lung Non-Small Cell Squamous Cancer	EGFR exon 19 deletion	Lung Non-Small Cell Squamous Cancer	EGFR inhibitor Sensitive: B - Late Trials EGFR inhibitor Sensitive : B	EGFR inhibitor Sensitive: B - Late Trials EGFR inhibitor Sensitive : B
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	aumolertinib Sensitive: B - Late Trials aumolertinib Sensitive : B	aumolertinib Sensitive: B - Late Trials aumolertinib Sensitive : B
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	furmonertinib Sensitive: B - Late Trials furmonertinib Sensitive : B	furmonertinib Sensitive: B - Late Trials furmonertinib Sensitive : B
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	befotertinib Sensitive: B - Late Trials befotertinib Sensitive : B	befotertinib Sensitive: B - Late Trials befotertinib Sensitive : B
EGFR exon 19 deletion	Lung Adenocarcinoma	EGFR exon 19 deletion	Lung Adenocarcinoma	osimertinib Sensitive: C1 - Off-label osimertinib Sensitive : C1	osimertinib Sensitive: C1 - Off-label osimertinib Sensitive : C1
EGFR exon 19 deletion	Small Cell Lung Cancer	EGFR exon 19 deletion	Small Cell Lung Cancer	gefitinib Sensitive: C1 - Off-label gefitinib Sensitive : C1	gefitinib Sensitive: C1 - Off-label gefitinib Sensitive : C1
EGFR exon 19 deletion	Lung Cancer	EGFR exon 19 deletion	Lung Cancer	gefitinib Sensitive: C1 - Off-label gefitinib Sensitive : C1	gefitinib Sensitive: C1 - Off-label gefitinib Sensitive : C1
EGFR exon 19 deletion	Small Cell Lung Cancer	EGFR exon 19 deletion	Small Cell Lung Cancer	osimertinib Sensitive: C1 - Off-label osimertinib Sensitive : C1	osimertinib Sensitive: C1 - Off-label osimertinib Sensitive : C1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	osimertinib + gefitinib Sensitive: C2 – Inclusion Criteria osimertinib + gefitinib Sensitive : C2	osimertinib + gefitinib Sensitive: C2 – Inclusion Criteria osimertinib + gefitinib Sensitive : C2
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	anlotinib + icotinib Sensitive: C2 – Inclusion Criteria anlotinib + icotinib Sensitive : C2	anlotinib + icotinib Sensitive: C2 – Inclusion Criteria anlotinib + icotinib Sensitive : C2
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGF816 Sensitive: C2 – Inclusion Criteria EGF816 Sensitive : C2	EGF816 Sensitive: C2 – Inclusion Criteria EGF816 Sensitive : C2
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	bevacizumab + osimertinib Sensitive: C2 – Inclusion Criteria bevacizumab + osimertinib Sensitive : C2	bevacizumab + osimertinib Sensitive: C2 – Inclusion Criteria bevacizumab + osimertinib Sensitive : C2
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	tislelizumab Sensitive: C2 – Inclusion Criteria tislelizumab Sensitive : C2	tislelizumab Sensitive: C2 – Inclusion Criteria tislelizumab Sensitive : C2
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	bevacizumab Sensitive: C2 – Inclusion Criteria bevacizumab Sensitive : C2	bevacizumab Sensitive: C2 – Inclusion Criteria bevacizumab Sensitive : C2
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	BBT-176 Sensitive: C2 – Inclusion Criteria BBT-176 Sensitive : C2	BBT-176 Sensitive: C2 – Inclusion Criteria BBT-176 Sensitive : C2
EGFR exon 19 deletion	Lung Non-Squamous Non-Small Cell Cancer	EGFR exon 19 deletion	Lung Non-Squamous Non-Small Cell Cancer	anlotinib + icotinib Sensitive: C2 – Inclusion Criteria anlotinib + icotinib Sensitive : C2	anlotinib + icotinib Sensitive: C2 – Inclusion Criteria anlotinib + icotinib Sensitive : C2
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	anlotinib + aumolertinib Sensitive: C2 – Inclusion Criteria anlotinib + aumolertinib Sensitive : C2	anlotinib + aumolertinib Sensitive: C2 – Inclusion Criteria anlotinib + aumolertinib Sensitive : C2
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3